Oral fecal microbiome transplantation, commonly known as poop pills, increased peanut tolerance in a subset of adults with a peanut allergy during a preliminary trial published August 5 in Science Translational Medicine. While the early-stage findings offer a potential new therapeutic avenue for the estimated up to 6 million people with allergic reactions to peanuts, medical experts emphasize that it is far too soon to recommend the capsules as a clinical treatment.
How the Fecal Microbiome Transplant Trial Worked
The human trial evaluated whether transferring stool samples from healthy donors without food allergies could reduce the severity of peanut reactions in allergic adults. According to study author Dr. Rima Rachid, the primary aim was evaluating safety in a food-allergic population, which showed that none of the patients experienced serious adverse events.
The trial was divided into two distinct stages. In the first phase, 10 individuals received frozen FMT from donors with healthy gut microbiomes, taking 36 pills in either 1 or 2 days. Four months later, 3 in 10 people experienced an increased tolerance to peanuts.
The Biological Mechanism: Gut Bacteria and Bile Acids
Researchers investigating the biological drivers behind the increased tolerance found that the treatment altered immune cell populations and metabolic pathways in both humans and mice.
This points to specific bacterial enzymes playing a critical role in mitigating food allergies, though this part of the study was not conducted in humans.
Expert Perspectives and Real-World Limitations
Despite the encouraging results, independent medical professionals urge caution regarding the current state of the research. Dr. Mohammad Bakhtiar, a general practitioner and clinical lead at Medical Express Clinic who wasn’t involved in the study, noted that the trial size is too small to draw sweeping conclusions.
“Six improved, but nine did not. It is still a tiny, open-label phase 1 study. I would treat it as an early signal, not a change in practice.”
Bakhtiar stressed that what people should do now remains unchanged: strict avoidance, an emergency plan, and specialist allergy care.
Future Outlook and Next Steps for Microbiome Therapies
Translating these early findings into a widely available commercial treatment will take considerable time and larger clinical investigations.
To move past whole-stool capsules, researchers are actively developing more purified interventions. MTT can be stored in a home fridge.
Experts estimate that if upcoming trials secure adequate funding and consistently replicate these protective effects, it’s possible we might see clinical applications in 10 to 15 years.
| Trial Stage | Participant Group | Positive Outcome |
|---|---|---|
| Stage One | 10 individuals taking frozen FMT capsules | 3 in 10 people experienced an increased tolerance to peanuts |
| Stage Two | 5 participants who had taken antibiotics before receiving FMT | 3 in 5 individuals had an increased peanut tolerance |
Frequently Asked Questions
What are “poop pills” in the context of peanut allergies?
Poop pills refer to oral fecal microbiome transplantation (FMT) capsules containing processed, healthy gut microbes from donors. They are designed to alter a patient’s gut microbiome to reduce immune reactivity to allergens like peanuts.
Were there any serious side effects reported in the study?
According to study author Dr. Rima Rachid, evaluating safety in the food allergic population was a first aim of the study, and none of the patients had serious adverse events.
Can I get a fecal transplant for a peanut allergy right now?
No. Medical experts emphasize that FMT cannot yet be recommended as a treatment for peanut allergy. What people should do now remains unchanged: strict avoidance, an emergency plan, and specialist allergy care.
How long until microbiome treatments for food allergies are available?
Join the Conversation: What are your thoughts on utilizing microbiome therapies for severe food allergies? Share your perspective in the comments below, and subscribe to our health newsletter for the latest updates on clinical trials and medical research.
Worth a look